Baker Bros. Advisors LP Novavax Inc Transaction History

Baker Bros. Advisors LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$36.28 - $75.29 $1.75 Million - $3.63 Million	-48,168 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$134.56 - $217.97 $8.15 Million - $13.2 Million	-60,588 Reduced 55.71%	48,168 $6.89 Million
Q3 2021 Nov 15, 2021	SELL	$177.8 - $270.58 $6.22 Million - $9.47 Million	-35,000 Reduced 24.35%	108,756 $22.5 Million
Q1 2021 May 17, 2021	SELL	$112.98 - $319.93 $2.93 Million - $8.3 Million	-25,950 Reduced 15.29%	143,756 $26.1 Million
Q4 2020 Feb 16, 2021	SELL	$78.74 - $139.5 $1.39 Million - $2.46 Million	-17,670 Reduced 9.43%	169,706 $18.9 Million
Q3 2020 Nov 16, 2020	SELL	$79.44 - $178.51 $4.29 Million - $9.64 Million	-54,000 Reduced 22.37%	187,376 $20.3 Million
Q2 2020 Aug 14, 2020	BUY	$13.86 - $83.61 $3.35 Million - $20.2 Million	241,376 New	241,376 $20.1 Million

291

93.4M

6.95M

9.4M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $704M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.